협부지방유래 줄기세포의 골모세포 분화에 있어 심바스타틴과 BMP-2에 의한 발현유전자의 마이크로어레이를 이용한 분석 (Microarray Analysis of Gene Expression in Osteogenic Differentiation of Buccal fat Pad-Derived Stem Cells Treated with Simvastatin and BMP-2)

서지정보

· 발행기관 : 한국조직공학과 재생의학회
· 수록지 정보 : 조직공학과 재생의학 / 6권 / 4호 / 942 ~ 951페이지
· 저자명 : 권순길, 김창현, 박재억, 이길

초록

Bone morphogenetic protein-2(BMP-2) converts stem cell into osteoblast through Smad pathway. In the pathway, R-Smad(Smad1/5) joins with Co-Smad(Smad 4) in the cytoplasm, and they move to the nucleus after going through phosphorylation. Then, they join with Osterix, a transcription factor, with which they induce expression of the gene related to the osteoblast's phenotype. Simvastatin, one of the statin drugs and a 3-hydroxy-3-methylglutary coenzyme A (HMG-CoA) suppressor, has not only known for its efficacy for human hyperlipidemia treatment, but also for its function similar to that of BMP-2, inducing osteoblast differentiation. To compare such function of simvastatin to that of BMP-2, we analyzed the level of expressions of Smad 1/5 and Osterixt after treating stem cell originated from buccal fat with simvastatin or BMP-2. Stem cells were attained from human buccal fat. After going through three times of subculture, we treated each BMP-2 with 1 μM simvastatin or 100 ng/mL and collected the cells at 12 hr, 24 hr, 48 hr and 72 hr. Then, we analyzed the extent of Smad 1,5 and Osterix expression employing Reverse Transcription PCR and Western blot. Also, we analyzed if the up-regulation and/or down-regulation
exist for osteoblast’s phenotypic gene in 1 μM simvastatin-treated group(simvastatin group) and 100 ng/mL BMP-2 treated group(BMP-2 group) using microarray analysis. We observed increased expression of Smad 1/5 and Osterix at 24hr in both simvastatin group and BMP-2 group. However, Smad 1/5 and Osterix expressions decreased in BMP-2 group at 72 hr. We saw same pattern of Smad 1/5 and Osterix expressions in microarray analysis. We observed the similar pattern of osteoblast's phenotypic gene expressions in simvastatin group and BMP-2 group. However, simvastatin group lasted longer than the BMP-2 group. Therefore, we see simvastatin as a potential candidate to replace BMP-2 as a osteoblast differentiation factor.

영어초록

Bone morphogenetic protein-2(BMP-2) converts stem cell into osteoblast through Smad pathway. In the pathway, R-Smad(Smad1/5) joins with Co-Smad(Smad 4) in the cytoplasm, and they move to the nucleus after going through phosphorylation. Then, they join with Osterix, a transcription factor, with which they induce expression of the gene related to the osteoblast's phenotype. Simvastatin, one of the statin drugs and a 3-hydroxy-3-methylglutary coenzyme A (HMG-CoA) suppressor, has not only known for its efficacy for human hyperlipidemia treatment, but also for its function similar to that of BMP-2, inducing osteoblast differentiation. To compare such function of simvastatin to that of BMP-2, we analyzed the level of expressions of Smad 1/5 and Osterixt after treating stem cell originated from buccal fat with simvastatin or BMP-2. Stem cells were attained from human buccal fat. After going through three times of subculture, we treated each BMP-2 with 1 μM simvastatin or 100 ng/mL and collected the cells at 12 hr, 24 hr, 48 hr and 72 hr. Then, we analyzed the extent of Smad 1,5 and Osterix expression employing Reverse Transcription PCR and Western blot. Also, we analyzed if the up-regulation and/or down-regulation
exist for osteoblast’s phenotypic gene in 1 μM simvastatin-treated group(simvastatin group) and 100 ng/mL BMP-2 treated group(BMP-2 group) using microarray analysis. We observed increased expression of Smad 1/5 and Osterix at 24hr in both simvastatin group and BMP-2 group. However, Smad 1/5 and Osterix expressions decreased in BMP-2 group at 72 hr. We saw same pattern of Smad 1/5 and Osterix expressions in microarray analysis. We observed the similar pattern of osteoblast's phenotypic gene expressions in simvastatin group and BMP-2 group. However, simvastatin group lasted longer than the BMP-2 group. Therefore, we see simvastatin as a potential candidate to replace BMP-2 as a osteoblast differentiation factor.

참고자료

· 없음